Introduction

Fragile X Syndrome (FXS) is a genetic condition characterised by intellectual disability, developmental delays, and specific physical features. It is caused by a mutation in the Fragile X Mental Retardation 1 (FMR1) gene, which is found on the X chromosome. The inheritance pattern of FXS is unique due to the mutation's nature and the X chromosome's role in genetic inheritance.

Understanding the inheritance patterns of FXS is crucial for both affected individuals and their families, not only for comprehensive clinical management to help navigate the complexities of the disorder but also for informed family planning decisions. Furthermore, it contributes to understanding the underlying genetic mechanisms of FXS, which can lead to the development of targeted treatments and interventions to improve the quality of life for affected individuals.

Basics of Genetics

Genes carry specific instructions encoded in DNA, which is the material that makes up our genetic code. For instance, as arranging puzzle pieces creates a picture, genes combine to form the intricate blueprint of living organisms. These genetic instructions dictate our specific characteristics, from our physical features to our susceptibility to certain diseases. These genes are bundled into structures called chromosomes. Humans have 23 pairs of chromosomes of which one pair is the sex chromosomes – X and Y. Males have one X and one Y chromosome, whilst females have two X chromosomes.

Understanding Fragile X Syndrome

FXS is one of the most prevalent genetic disorders causing developmental disabilities and intellectual impairments and the most common single-gene cause of autism spectrum disorder.¹

FXS has an approximate prevalence of 1 in 5000 in males versus 1 in 8000 in females.² 

FXS is caused by a mutation in the FMR1 gene located on the X chromosome. This mutation leads to a deficiency in fragile X mental retardation protein (FMRP), which plays a crucial role in brain development and function.

Individuals with FXS may exhibit a range of symptoms, including learning disabilities, social and behavioural challenges, speech and language delays, anxiety, hyperactivity, and distinctive physical features such as a long face, large ears, and a prominent jaw. The severity of symptoms can vary widely among affected individuals, ranging from mild to severe.³ 

Genetics of Fragile X Syndrome

FXS is primarily caused by a mutation in the FMR1 gene, which is located on the X chromosome. This gene encodes the fragile X mental retardation protein (FMRP), crucial for brain development and function, particularly in regulating the communication between nerve cells.

The FMR1 gene is located on the long arm of the X chromosome (Xq27.3). It contains a specific DNA sequence known as cytosine-guanine-guanine (CGG) repeats. In individuals without FXS, the FMR1 gene typically contains between 5 to 44 CGG repeats. However, in individuals with FXS, there is an abnormal expansion of the CGG repeat sequence, resulting in more than 200 repeats. This expansion leads to gene silencing and a deficiency in FMRP production.

FMRP is critical for normal brain development. It regulates the timing and balance of protein production within nerve cells, which is crucial for various cognitive processes like learning and memory. The absence of FMRP disrupts the growth, communication, and function of brain cells, leading to cognitive and behavioural impairments.⁴ 

Inheritance Pattern

FXS typically follows an X-linked dominant inheritance pattern.⁵ This means that the mutated gene is located on the X chromosome, and only one copy of the mutated gene is sufficient to cause the disorder. In males, inheriting the mutated gene results in FXS. In females, the presence of a mutated gene on one of the X chromosomes is also sufficient to cause the disorder, however, the severity of FXS varies depending on whether one or both X chromosomes carry the mutation. If one X chromosome carries the mutated FMR1 gene and the other X chromosome carries a normal copy of the gene, this may provide enough normal FMRP, reducing the severity of FXS symptoms.⁶

Furthermore, females may exhibit milder symptoms due to X-chromosome inactivation, a process by which one of the X chromosomes in each cell is randomly silenced during early development.⁷

Variable expression and penetrance

FXS exhibits variable expression and penetrance, that is the severity of symptoms and the likelihood of developing the disorder can vary widely among individuals carrying the mutated gene. Factors such as the number of CGG repeats, genetic background, and environmental influences contribute to this variability. Some individuals may have mild cognitive impairment, whilst others may experience more significant challenges, such as severe intellectual disabilities.⁸

This variability poses challenges for diagnosis and treatment, but it highlights the importance of personalised care for individuals with FXS.

FXS impact on successive generations

FXS exhibits a phenomenon known as genetic anticipation, which refers to the tendency for the disease to become more severe and symptoms to appear at an earlier age in successive generations. This is associated with the number of CGG repeats, which often expand when the mutation is passed from one generation to the next. As a result, individuals with FXS may have children who are more severely affected than themselves.⁹ 

Genetic anticipation highlights the dynamic nature of FXS and underscores the need for ongoing monitoring and support for affected families.

Other Inheritance Forms

Whilst FXS is primarily caused by a mutation in the FMR1 gene on the X chromosome, which follows an X-linked dominant pattern of inheritance, there are additional complexities to its inheritance.

Carriers

Females with one normal X chromosome and one X chromosome with an expanded CGG repeat in the FMR1 gene are carriers of FXS, even if they do not exhibit symptoms of the disorder themselves. Carriers can pass the mutated gene on to their children, increasing the risk of FXS in subsequent generations.¹⁰ 

The likelihood of passing on the mutated FMR1 gene to offspring depends on several factors, including the gender of the carrier and the size of the CGG repeat expansion. Generally, larger expansions are associated with a higher risk of transmission. Additionally, the process of X-chromosome inactivation in females can influence the phenotypic expression and severity of symptoms in affected offspring.⁷ 

Genetic counselling is extremely important for carriers of FXS, as it provides comprehensive information and support regarding the risk of transmitting the mutated gene to offspring. Genetic counsellors can help carriers understand their individual risk based on factors such as CGG repeat size and provide guidance on reproductive options, such as prenatal testing and preimplantation genetic diagnosis. Additionally, genetic counsellors can offer resources and support for carriers and their families, including access to specialised medical care and community support groups.¹¹ 

Unstable Repeat Expansion

FXS can also occur due to a spontaneous expansion of CGG repeats in the FMR1 gene during reproduction. This means that even if neither parent has the full mutation, a child can develop FXS if there is an expansion of CGG repeats during the formation of reproductive cells (eggs or sperm).¹² 

Mosaicism

In some cases, individuals may have a mixture of cells with different numbers of CGG repeats, that is, some cells have a mutation, whilst others have a normal number of repeats. This is known as mosaicism. Mosaicism can lead to variations in the severity of symptoms of FXS, and it can also affect the inheritance pattern. For instance, the inheritance pattern may differ depending on which cells contribute to the formation of reproductive cells. Therefore, some people may have mild symptoms, whilst others may have more severe ones.¹³ 

Diagnosis and Management

Diagnosing FXS typically involves genetic testing to identify the mutation in the FMR1 gene. This testing can determine if an individual has FXS or is a carrier of the mutation.¹⁴

Whilst there is no cure for FXS, there are various interventions available to help manage symptoms and improve quality of life.¹⁵ These may include:

• Behavioural therapies, including applied behavioural analysis, speech therapy, occupational therapy, cognitive-behavioural therapy, and social skills training
• Medications to address specific symptoms like anxiety or ADHD
• Educational interventions, including individualised education plans

Ongoing research into the genetics of FXS continues to advance our understanding of the condition and potential treatment options aimed at addressing the underlying causes of FXS, including gene therapy and targeted drug treatments.³

Families affected by FXS often benefit from access to support services and resources, such as:

• Support groups for affected individuals and families to connect with other people facing similar challenges
• Advocacy organisations that provide information, resources, and research updates related to FXS

Additionally, healthcare providers, genetic counsellors, educators, and social workers can offer valuable support and guidance to affected individuals and families navigating the complexities of FXS.

Conclusion

Understanding the inheritance patterns of Fragile X Syndrome is crucial for affected individuals and their families. FXS is caused by the expansion of CGG trinucleotide repeats in the FMR1 gene and it follows an X-linked inheritance pattern, with variable expression and the potential for genetic anticipation. Genetic testing and counselling can provide valuable information for families affected by FXS, helping them make informed decisions about their future. Whilst there is currently no cure for FXS, early diagnosis, intervention, and support services can significantly improve outcomes and quality of life for individuals living with the condition.